

Declaration of Interests Register

TA Committee C

Publication Date: 01/07/2020

Topic: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID1504]

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Michael Chambers	TAC Committee Member	Direct - financial	Received consultancy fee from Roche Products, although he had not been involved directly with the product under discussion.	July 2017	10/09/2019 & 14/11/2019	Not specified	It was agreed that this declaration would not prevent Michael Chambers from participating in this section of the meeting.
Richard Nicholas	TAC Committee Member	Non-specific	Worked on a trial committee in an unrelated disease area with Roche Products	Not specified	21/11/2019	Not specified	It was agreed that this declaration would not prevent Richard Nicholas from participating in this section of the meeting.
Samreen Ahmed	Clinical expert	Direct - financial	Received consultancy and speaker fees from Roche Products	Not specified	02/10/2019	Not specified	It was agreed that this declaration would not prevent Samreen Ahmed from participating in this section of the meeting.
Alistair Greystoke	Clinical expert	Direct - financial	Received consultancy and speaker fees from Roche Products. Received	Not specified	02/10/2019	Not specified	It was agreed that this declaration would not prevent Alastair Greystoke from

			consultancy fees for a similar technology from Astrazeneca				participating in this section of the meeting.
--	--	--	--	--	--	--	---

Link to Committee C interests register : <https://www.nice.org.uk/Media/Default/Get-involved/Meetings-In-Public/Technology-appraisal-committee/TAC-C-interests-register.pdf>